Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

Inspira Technologies (NASDAQ: IINN) will showcase its FDA-cleared ART100 at AmSECT 64th International Conference, March 25–29, 2026, in Austin, Texas, via U.S. distributor Glo-Med Networks.

Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) will showcase its FDA-cleared ART100 at AmSECT 64th International Conference, March 25–29, 2026, in Austin, Texas, via U.S. distributor Glo-Med Networks.

The company is targeting perfusionists and cardiac surgical teams to accelerate U.S. commercial adoption, leveraging its FDA 510(k) clearance (May 2024) and active distribution channel for clinical integration.

Argus Feb 17 session

+0.85% close to close Open Argus

Details

News Market Reaction – IINN

On Feb 17, the day this news came out, IINN closed 0.85% above the previous close.

Data tracked by StockTitan Argus for the Feb 17 session.

Key Figures

Conference edition: 64th Conference dates: March 25–29, 2026 FDA clearance date: May 2024

Conference edition

64th

American Society of Extracorporeal Technology International Conference

Conference dates

March 25–29, 2026

AmSECT 64th International Conference in Austin, Texas

FDA clearance date

May 2024

ART100 received FDA 510(k) clearance

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Nasdaq compliance notice

   24h Move

   -3.9%

   Nasdaq notified IINN of failure to meet $1.00 minimum bid requirement.

2. Feb 09

   Major HMO vendor win

   24h Move

   -5.6%

   Clalit vendor approval enabling immediate ART100 deployment across its network.

3. Feb 05

   Registered direct & PIPE

   24h Move

   -6.5%

   Pricing of $4.75M registered direct and concurrent warrant private placement.

4. Feb 03

   HYLA validation data

   24h Move

   +4.9%

   HYLA standalone blood sensor showed 94.2% pCO₂ accuracy targeting surgery market.

5. Jan 29

   ART100 hospital adoption

   24h Move

   -0.1%

   ART100 completed clinical evaluation and entered budgeted procurement at top U.S. center.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fda 510(k) clearance, extracorporeal, perfusionists, cardiopulmonary bypass

4 terms

fda 510(k) clearance regulatory

"The showcase capitalizes on the ART100’s FDA 510(k) clearance (received in May 2024)"

FDA 510(k) clearance is an official approval from the U.S. Food and Drug Administration that allows medical devices to be legally sold in the United States. It indicates the device is considered safe and effective based on its similarity to already approved products. For investors, achieving 510(k) clearance can signal a company's readiness to bring a medical device to market and generate revenue.

extracorporeal medical

"American Society of Extracorporeal Technology (AmSECT) 64th International Conference"

Extracorporeal describes medical treatments or devices that act on blood, organs, or tissues outside the body for a period of time, such as filtering, oxygenating, or warming blood using a machine. Investors care because extracorporeal technologies form a distinct product market with specific regulatory paths, manufacturing needs, and recurring revenue from disposables; think of it like a laundromat for the body's fluids—specialized equipment doing work externally that patients and hospitals must repeatedly buy or use.

perfusionists medical

"premier global venue for perfusionists and cardiac surgical teams who directly"

Perfusionists are trained clinical specialists who operate and manage the machines that take over a patient’s heart and lung functions during complex surgeries, such as open-heart procedures; think of them as the pilots of the heart–lung machine. Investors care because perfusionists are essential to the capacity, safety and outcomes of cardiac and certain transplant surgeries, and shortages or changes in their availability, training costs, or technology can affect hospital costs, procedure volume and revenue.

cardiopulmonary bypass medical

"integration in cardiopulmonary bypass procedures.Active Distribution Channel"

Cardiopulmonary bypass is a medical procedure where a machine temporarily takes over the heart and lungs during major surgery, circulating and oxygenating the blood so surgeons can operate on a still, blood-free heart. Investors care because the technique drives demand for specialized equipment, disposables, training and hospital services, and changes in safety, regulation, procedure volumes or technology can materially affect the revenues and costs of device makers and healthcare providers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies,” “Inspira,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic commercial showcase of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system. The system will be featured at the American Society of Extracorporeal Technology (AmSECT) 64th International Conference, taking place March 25–29, 2026, in Austin, Texas, at the exhibition booth of its U.S. distributor, Glo-Med Networks Inc. (“Glo-Med”).

Key Commercial Highlights:

• Targeting Clinical Decision Makers: The ART100 will be positioned at AmSECT, the premier global venue for perfusionists and cardiac surgical teams who directly influence hospital purchasing decisions.
• Leveraging FDA Clearance: The showcase capitalizes on the ART100’s FDA 510(k) clearance (received in May 2024) to validate the system’s readiness for immediate clinical integration in cardiopulmonary bypass procedures.
• Active Distribution Channel: The presentation via Glo-Med demonstrates an active commercial pipeline, moving beyond development into sales execution and market visibility.

“We are moving fast to translate our FDA clearance into market share. Presenting the ART100 alongside Glo-Med at AmSECT allows us to engage directly with the decision-makers who drive hospital purchasing,” said Mike Hershkovitz, Global VP Sales at Inspira Technologies. “This event marks a key phase in our U.S. commercial strategy as we expand our clinical partnerships and distribution footprint.”

Commercial and Clinical Inquiries Perfusion leaders, hospital administrators, and industry partners interested in scheduling a meeting with Mr. Hershkovitz during the conference are invited to contact: mike@inspirao2.com.

About the 64th AmSECT International Conference
The AmSECT International Conference is the definitive global event for perfusion technology. Taking place March 25–29, 2026, in Austin, Texas, the conference features cutting-edge medical technologies and expert-led sessions shaping the future of extracorporeal circulation and patient care.

About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses benefits and advantages of the ART100 system, its active commercial pipeline, the move into sales execution and market visibility and that it is actively expanding its clinical partnerships and distribution footprint in the U.S.. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Inspira (IINN) present at AmSECT 2026 and when is it happening?

Inspira will showcase the FDA-cleared ART100 at AmSECT March 25–29, 2026. According to the company, the presentation occurs at the Glo-Med Networks booth in Austin, Texas, to engage perfusionists and cardiac surgical teams who influence hospital purchasing.

How does the ART100's FDA 510(k) clearance affect Inspira's (IINN) U.S. commercial plans?

The FDA 510(k) clearance enables immediate clinical integration and market engagement. According to the company, Inspira is leveraging the May 2024 clearance to validate readiness and accelerate adoption through distributor-led demonstrations.

Who is distributing Inspira ART100 in the U.S. and what is their role at AmSECT 2026?

Glo-Med Networks is the U.S. distributor presenting ART100 at AmSECT. According to the company, Glo-Med’s booth will host demonstrations and meetings to move the product from development into active commercial channels.

Which clinical audiences is Inspira (IINN) targeting at the AmSECT conference?

Inspira is targeting perfusionists and cardiac surgical teams who influence hospital purchasing decisions. According to the company, engaging these clinical decision-makers aims to accelerate hospital adoption and distribution partnerships.

How can investors or clinicians schedule a meeting with Inspira (IINN) at AmSECT 2026?

Meetings can be arranged by contacting the company directly via the provided email for conference inquiries. According to the company, interested perfusion leaders and hospital administrators should email mike@inspirao2.com to request a meeting.